Navigation Links
Ohio State and Moffitt form world's largest cancer research collaboration for big data
Date:5/30/2014

TAMPA, Fla., and COLUMBUS, Ohio (May 28, 2014) Two of North America's leading cancer centers, Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), today announced what is likely the largest collaboration of its kind to accelerate discoveries in cancer research.

Named the Oncology Research Information Exchange Network (ORIEN), the new partnership will launch with over 100,000 consented patients who have agreed to donate their tissue and clinical data for research to understand cancer at the molecular level. ORIEN will utilize a single protocol, Total Cancer Care, to create a collaborative, "rapid learning" environment that will share de-identified data to accelerate the development of targeted treatments, allowing researchers and clinicians to more quickly match eligible patients to clinical trials and conduct larger and richer analysis.

National System Long Overdue

Leaders of each cancer center emphasized ORIEN's goal to develop more precise ways to prevent, detect, diagnose, and treat cancers.

"Cancer is a highly complex disease, and potential breakthroughs have been stalled because we've lacked an efficient way to share incremental insights," said Alan F. List, M.D., president and CEO of Moffitt. "Even more frustrating, until today we've had no system to quickly match cancer patients from anywhere in the country with ongoing clinical research with the most potential to help them," he said. "By partnering with The Ohio State University through ORIEN, we've built a cancer research expressway."

"With ORIEN, we're amassing a true national cancer database for the first time," said Michael Caligiuri, M.D., director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital. "The collaboration across academic centers and with health care industry will not only help speed discovery, but will also provide patients with more personalized treatment options and ultimately, lead to better outcomes."

Through data analysis and sharing, ORIEN will provide physicians evidence of the best therapeutic options, including clinical trial treatments, specific to a patient's biological and epidemiological profile, increasing the likelihood of treatment efficacy, speeding response time, and potentially minimizing side effects while improving outcomes.

Patients are followed throughout their lifetime and can play an active role in the study of their cancer and improve care for future generations.

ORIEN builds upon the strengths of its founders' National Cancer Institute-designated comprehensive cancer centers: Moffitt's Total Cancer Care protocol, biorepository and data warehouse of patients' genotypic and phenotypic data, and OSUCCC-James's depth and breadth in translating molecular- and genetic-based discoveries into more effective ways to prevent, detect, treat and ultimately cure cancers. M2Gen, a subsidiary of Moffitt, will serve as ORIEN's operational and commercial provider for support, bringing expertise in data management and informatics.

The ORIEN collaborative will seek partnerships with other leading cancer centers in North America. More information may be found at ORIENcancer.org.

Clinical Trial Matching

ORIEN's approach to clinical trial matching also presents a significant opportunity for pharmaceutical companies to modernize trial recruitment and facilitate adaptive clinical trial design. Through M2Gen, industry researchers will be able to match their targeted drugs to participating patients within ORIEN cancer center members based on their molecular profile, promoting greater trial efficiency and flexibility. Ultimately, researchers will be better equipped to identify potential candidates for their drug trials, leading to better outcomes. ORIEN also creates the ability to accelerate and improve efficiencies of clinical trials and the drug approval process, including post-market surveillance.

"M2Gen will facilitate what we view as the ideal way to conduct cancer research and help patients an approach that promotes collaborative learning at all levels," said William S. Dalton, Ph.D., M.D., president and CEO of M2Gen. "The goal of our joint efforts with Moffitt and OSUCCC-James is to connect patients to the best treatment options, including clinical trials, by accelerating the discovery and delivery of personalized medicine."


'/>"/>

Contact: Kim Polacek
Kim.Polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Radiation for prostate cancer linked to secondary cancers, study finds
2. Study affirms value of epigenetic test for markers of prostate cancer
3. Study shows image fusion-guided biopsy improves accuracy of prostate cancer diagnosis
4. Phase III clinical trial shows image fusion-guided biopsy significantly improves accuracy of prostate
5. Prolaris® test predicts mortality risk in prostate cancer biopsy study
6. Robot-assisted prostate cancer surgery as safe but more expensive as open surgery in older men
7. Low risk prostate cancer not always low risk
8. MicroRNA that could be used to suppress prostate cancer progression found
9. Identified 2 new genes involved in the more aggressive prostate cancer
10. Older, sicker men with early-stage prostate cancer do not benefit from aggressive treatment
11. Two genes together drive aggressive prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... , ... May 22, 2017 , ... ... is now welcoming new patients with periodontal plastic surgery treatments, including crown ... general dentist. Dr. Green provides these esthetic and functional procedures to help patients ...
(Date:5/22/2017)... ... ... Faithfully following pop culture, people today are forever in pursuit of physical ... programs. It carries on to skin nourished, pampered and nurtured to be soft and ... CDA has found that just like a perfectly cut and polished diamond, that ...
(Date:5/21/2017)... , ... May 20, 2017 , ... ... systems between ABC Financial Services and financial systems. , Dozens of ... exported files that are electronically processed through GetLinked into their club’s accounting system ...
(Date:5/21/2017)... ... ... For more than 20 years United Cutlery has been distinguished by unique ... functional to fantasy. United Cutlery has always been “Stronger. Sharper” than the competition and ... Offering a range of weapons and tools built for battle, the M48 line by ...
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... ... RawTrition’s BioEnergy in an upcoming episode of Innovations with Ed Begley, Jr., airing ... RawTrition is the distributor of a clean, organic dietary supplement made from naturally ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... 5, 2017  May is Stroke Awareness Month and ... most important methods to prevent a stroke: monitor and ... Disease Control and Prevention, undetected and uncontrolled hypertension is ... the global leader in personal heart health technology, recently ... heart attack and stroke and is advancing a national ...
(Date:5/4/2017)... and SAN DIEGO , May ... Gynecologists (ACOG) 2017 Annual Clinical and Scientific Meeting— OBP ... illuminating medical devices, today announced the launch of a ... OfficeSPEC and ER-SPEC vaginal specula. ... of extra-small and extra-large sizes makes OBP Medical,s line ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
Breaking Medicine Technology: